A5056065048- Nausea and vomiting management
- Pharmaceutical studies and practices
- Anesthesia and Pain Management
- Childhood Cancer Survivors' Quality of Life
- Palliative Care and End-of-Life Issues
- Pediatric Pain Management Techniques
- Pharmacological Effects and Toxicity Studies
- Pharmaceutical Practices and Patient Outcomes
- Family and Patient Care in Intensive Care Units
- Child Therapy and Development
- Antifungal resistance and susceptibility
- Neutropenia and Cancer Infections
- Colorectal Cancer Treatments and Studies
- Acute Lymphoblastic Leukemia research
- Counseling, Therapy, and Family Dynamics
- Vitamin C and Antioxidants Research
- Electrolyte and hormonal disorders
- Safe Handling of Antineoplastic Drugs
- Pharmaceutical Economics and Policy
- Hepatocellular Carcinoma Treatment and Prognosis
- Art Therapy and Mental Health
- COVID-19 Clinical Research Studies
- Vitamin D Research Studies
- Pancreatic and Hepatic Oncology Research
- COVID-19 and Mental Health
Memorial Sloan Kettering Cancer Center
2013-2024
Saint Louis University
2023
The safe use of medications in pediatric patients requires practitioners to consider the unique pharmacokinetics and pharmacodynamics drugs prescribed this age group. In an effort create a standard care for population, list that are potentially inappropriate has been developed titled "KIDs List."A panel 7 pharmacists from Pediatric Pharmacy Association were recruited evaluate primary, secondary, tertiary literature; FDA Safety Communications; Lexicomp electronic database; product information...
Abstract This clinical practice guideline (CPG) provides clinicians with recommendations regarding chemotherapy emetogenicity classification in pediatric oncology patients. information is critically important for the appropriate selection of antiemetic prophylaxis. Recommendations are based on a systematic review limited to patients and framework when prophylaxis provided. Findings 87 publications informed 49 single‐agent 13 combination‐agent regimens. Information required many...
This clinical practice guideline provides recommendations for preventing acute and delayed phase chemotherapy-induced nausea vomiting (CINV) in pediatric patients. The are based on two systematic reviews of randomized controlled trials evaluating interventions to prevent (1) CINV (2) CINV. Recommendations prophylaxis made patients receiving chemotherapy varying emetogenicity, as well not able receive dexamethasone or a neurokinin-1 receptor antagonist. Evidence gaps, including antiemetic...
Background This retrospective review provides preliminary data regarding the safety and efficacy of olanzapine for chemotherapy‐induced vomiting (CIV) control in children. Procedure Children <18 years old who received acute nausea (CINV) from December 2010 to August 2013 at four institutions were identified. Patient characteristics, chemotherapy, antiemetic prophylaxis, dosing, CIV control, liver function test results adverse events abstracted health record. Toxicity was graded using...
Abstract This clinical practice guideline update provides recommendations for treating breakthrough chemotherapy‐induced nausea and vomiting (CINV) preventing refractory CINV in pediatric patients. Two systematic reviews of randomized controlled trials adult patients informed the recommendations. In with CINV, escalation antiemetic agents to those recommended chemotherapy next higher level emetogenic risk is strongly recommended. A similar recommendation escalate therapy made prevent who did...
Abstract This 2021 clinical practice guideline update provides recommendations for preventing anticipatory chemotherapy‐induced nausea and vomiting (CINV) in pediatric patients. Recommendations are based on systematic reviews that identified (1) if a history of acute or delayed CINV is risk factor CINV, (2) interventions prevention treatment. A strong recommendation to optimize control order prevent made. Conditional made hypnosis, desensitization, relaxation techniques, lorazepam the...
Purpose With the rapid spread of COVID-19 in New York City since early March 2020, innovative measures were needed for clinical pharmacy specialists to provide direct care safely cancer patients. Allocating workforce was necessary meet surging needs inpatient services due outbreak, which had potential compromise outpatient services. We present here our approach restructuring and providing patient clinics during pandemic. Data sources conducted a retrospective review electronic documentation...
Limited data on optimal posaconazole dosing strategies for pediatric patients exist. In this study, we found that the median initial dose in who achieved a plasma concentration of 0.7 μg/mL was 22.8 mg/kg per day whereas those did not reach target 15.8 day; result suggests higher doses might be warranted.
The number of drug shortages quadrupled from 2004, with 58 shortages, to 267 in 2011.1 Eighty percent the 127 studied 2010–11 involved sterile injections, and leading causes for reported injection included problems at manufacturing facility (43%), delays or shipping (15%), active pharmaceutical ingredients (10%).2 Sterile injectables have unique market features that make such products more likely occur harder prevent. There are few manufacturers generic injectable products, top three holding...
Article Tools CASE REPORTS OPTIONS & TOOLS Export Citation Track Add To Favorites Rights Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00442 JCO Precision Oncology no. 7 (2023) e2200442. Published online February 27, 2023. PMID: 36848609 Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine Melissa Lumish , MD1xMelissa LumishSearch for by this author;...
Due to an evidence gap, the emetogenicity of intravenous (IV) pegaspargase was unable be included in clinical practice guideline classifying chemotherapy pediatric patients. This single-center, retrospective chart review describes proportion patients who did not vomit during acute phase (complete response; CR) after receiving IV and provides classification using a preexisting framework. Of 44 received between 2011 2020, 13 serotonin receptor antagonist plus dexamethasone or palonosetron...
Children's Oncology Group (COG) pharmacists and pharmacy technicians from more than 200 COG-member institutions comprise the COG Pharmacy Discipline. Discipline members serve an essential role in design execution of clinical trials. Core activities include study drug management, access, trial operations, protocol harmonization, direct patient care. are also actively involved continuing education, membership engagement, research across other committees/domains. Future areas committed growth...
The purpose of this study was to investigate the effectiveness art-play therapy and story on problems children with cancer admitted hospital. This a semi-experimental, post-test-pre-test control group. statistical population research contains all who were in children's In study, by using purposeful sampling method, desired samples selected replaced three groups simple random
10575 Background: Recent NCCN guidelines recommend the addition of a neurokinin-1(NK1) receptor antagonist (e.g. fosaprepitant) to serotonin 5-hydroxytryptamine type 3 (5-HT3) antagonist-corticosteroid combination for controlling both acute and delayed chemotherapy induced nausea vomiting(CINV) associated with high emetogenic (HEC) in adults. Fosaprepitant is bioequivalent aprepitant could offer benefits patients who are unable tolerate oral antiemetics. However, little known about efficacy...